Currently Schwab has earnings per share at .3.87 cents. P&E 10.07

Fidelity and schwab has 10 pe

Charles Schwab has pe at 9.54 too. This thing is way below fair value.

Stop crying over price drop. You can add and lower your cost average. You don't make or lose any money until you sell or it's bought out. There is no way it will sell at this price. Suck it up if you don't sell your going to do fine. The company is profitable and revenue is growing.

Hard to say without knowing who they are.

The ones running this shouldn't be selling but buying

Damn. How much more can it fall? Ive lost my life savings.

Dude you need serous help. Please get some. Your rants are worrisome.

Check out Ole 1.50 posts on other stocks. Basher on dozens of other stocks besides eltp! Trashes every single one

No more on it was AI generated. You hate this so bad sell and more on. Is this IB or Snup or one of your other alias?

AI Overview


+12
It is impossible to provide a definitive "fair" buyout offer for Elite Pharmaceuticals (ELTP) stock, as this is a forward-looking financial prediction dependent on numerous market factors and non-public information. However, recent analyst and market speculation suggests potential buyout price targets ranging from approximately $2.67 to over $18 per share, depending heavily on the potential buyer (domestic vs. foreign) and future business success.

Key Information Regarding ELTP
Current Status: Elite Pharmaceuticals is a specialty pharmaceutical company developing niche generic products, trading on the OTC Markets under the ticker ELTP. As of November 17, 2025, its stock price was around $0.58-$0.68 per share.
M&A Activity: In its Q4 2025 earnings report, Elite announced it was engaging a financial advisor to explore mergers and acquisitions (M&A) or a Nasdaq uplisting, with a decision expected in the coming months. This officially puts the company in play for a potential buyout.
Growth & Pipeline: The company has reported strong revenue growth, including a significant 92% increase in Q2 2026 revenue, driven by new product launches like generic Lisdexamfetamine. This growth makes it an attractive target for larger pharmaceutical companies.
Potential Buyout Valuations (Speculative)
Market analyses and forum discussions have proposed a wide range of potential buyout prices, which are highly speculative:
Domestic Buyer (Lower End): Some estimates for a domestic buyer, based on traditional revenue multiples, range from $2.67 to $4.57 per share.
Strategic Acquisition (Analyst Targets): Based on projected revenue increases and a forward-looking approach, a buyout price for a strategically valuable acquisition could range between $8 to $10 per share.
Foreign Buyer (High End): Highly optimistic scenarios, which assume a foreign buyer would pay a significant premium to leverage U.S. manufacturing to avoid high tariffs, predict valuations possibly reaching $18-$20 per share. This would represent a substantial premium over its current trading price.
Important Caveats
Forward-Looking: These figures are speculative and based on various assumptions about future earnings, market conditions, and potential buyer intent.
Market Risk: ELTP is an over-the-counter (OTC) stock, which can be subject to higher volatility and risks compared to stocks on major exchanges like the Nasdaq or NYSE.
Not Financial Advice: This information does not constitute financial advice. Investors should perform their own due diligence or consult with a qualified financial advisor before making any investment decisions, as stock values can fluctuate widely.
For the latest official news and financial data,

This was AI generated
Pharmaceutical companies that could benefit most from acquiring Elite Pharmaceuticals (ELTP) are primarily those looking to expand their generic drug portfolios, particularly in the high-demand ADHD and pain management markets, or companies with a strategic interest in domestic U.S. manufacturing.
Based on market analysis and speculation, potential domestic buyers could include major players like Pfizer and Johnson & Johnson, while international companies like Dr. Reddys or Teva Pharmaceuticals might also be interested.
Strategic Rationale for Potential Acquirers
An acquisition of Elite Pharmaceuticals would offer several strategic advantages to a larger pharmaceutical company:
Established Generic Portfolio: Elite has a solid presence in the generic market, notably holding approximately 20% market share in mixed amphetamine immediate-release (IR) tablets (generic Adderall IR) and a 16% share in the extended-release (XR) capsules. This provides an immediate, stable revenue stream.
Pipeline and Market Share Expansion: Elite has a pipeline of high-potential generic drugs, including generic versions of Vyvanse (for ADHD) and various pain management medications like generic OxyContin, Percocet, Norco, and Methadone. Acquiring Elite would grant access to these products and their associated market shares, including a potential 180-day exclusivity for generic OxyContin.
Domestic Manufacturing Footprint: With recent political and economic discussions favoring domestic manufacturing to mitigate tariff risks, companies with U.S.-based facilities, such as Elite, are attractive acquisition targets. Major domestic manufacturers like Eli Lilly, Vertex, and AbbVie have been identified as potential winners in a shifting landscape, and an acquisition could bolster a larger firm's U.S. operations.
Margin Accretion: Elite's management has indicated that its products offer favorable and margin-accretive contributions, which could improve the overall profitability of a larger entity.
Summary of Potential Suitors
Company Category Potential Suitors (Speculative) Key Benefit of Acquisition
Major Domestic Pharma Pfizer, Johnson & Johnson Immediate generic market share, domestic manufacturing boost, pipeline integration
International Pharma Dr. Reddys, Teva Pharmaceuticals U.S. market access and expansion, product diversification
Other Large Pharma Eli Lilly, AbbVie, Novartis Diversification from current core focus (e.g., obesity drugs for Lilly/Novo Nordisk), cash flow generation, and potential risk mitigation
Ultimately, the most suitable acquirer would be a company that can leverage Elite's specific product mix and manufacturing capabilities to fill a gap in its own portfolio or expand its market reach in a cost-effective manner.
AI responses may include mistakes. For financial advice, consult a professional.

Loading up here.l9l

Maybe we don't have to wait 3 months. He has already done one walk through for an unsolicited company and expects to do another walk through by the end of the year. That's 2 companies interested. We could get an offer anytime!

It's good to see others know how it works. I'm Loving the upside from here. Hate to be out right now when offer can come anyday!

Naz seemed really excited when talking about the interest in eltp

I am buying here . Loved hearing about the interest in buying company

Why are you lying

Yeah but the pullback and highs keep moving higher

Bid 1,000,000 shares @ .61 now

Bid 1,000,000 shares @ .61 now

Now bid is 1 mil @ .607

1,000,000 share buy @ .6065 up now

The 2 mil @ .6057 was up on schwab for 5 min then lowered to 1.3 min for 5 min then disappeared

Yeah they dropped it to 1.3 million then removed it

Someone just put in a buy for 2,000,000 shares! It's about to get real!!

Hey I just happy to pick up a few more shares here. I will be glad I did after conference call. All signs point blowout earnings

I disagree. I think the sp will go up with revenues going up triple digits y/y

I bought 100k shares yesterday too. I think today might be the start of the climb into CC. I have a good feeling with news out about shortages. Means didn't have to cut price and we sold all we were allowed to make.

GLTA

This thing is about to take off!!! Hate be the ones that sold here trying to buy lower and miss the low

After new info that came out looks like we may have bought just before a big climb up!"

I just picked up 100k shares under .60

Friday he said he had 400k to buy this week

I think the days of grabbing cheapies at .62 are over. In a couple weeks anything under .80 will be considered cheap.

2nd Qtr is in the books and with closing price yesterday 64 cents, revenues will soar. Let's say revenue stays the same warrants will add to that because of price drop from 73 to 64 qtr over qtr. This thing is about to explode over the next 6 weeks. Strap in this is about to get real! That's my opinion . What do others think?

No they are laughing at you!!!!!! I was day trading this for years while it was between 3 and 4 cents. I wouk buy 200k to 300k shares around 3 cents and dump at 4 cents rinse and repeat only made 1k or 2k a month but it adds up any stock that has 10% swings daily is perfect candidate to day trade.

You sound like a short or day trader saying shyt like that. So if it goes to .70 today is he still a bag holder? It takes someone buying at a new high to make it go higher.

Yeah a day trader

Bag holder only if price doesnt go up but if it hits a dollar that bag holder term doesn't work. Buffet says he buys things and others say he paid too much but a year later and it is a great buy! Your looking at it like a day trader. It only matters what it is when it sells

Simply Wallstreet has fair value for ELTP at 3.93.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-eltp/elite-pharmaceuticals/valuation